Neogenomics (NEO) Equity Ratio (2016 - 2025)
Neogenomics' Equity Ratio history spans 16 years, with the latest figure at 0.62 for Q4 2025.
- For Q4 2025, Equity Ratio rose 11.68% year-over-year to 0.62; the TTM value through Dec 2025 reached 0.62, up 11.68%, while the annual FY2025 figure was 0.62, 11.68% up from the prior year.
- Equity Ratio reached 0.62 in Q4 2025 per NEO's latest filing, up from 0.61 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.62 in Q4 2025 to a low of 0.55 in Q4 2024.
- Average Equity Ratio over 5 years is 0.58, with a median of 0.57 recorded in 2022.
- Peak YoY movement for Equity Ratio: tumbled 97.87% in 2021, then increased 11.68% in 2025.
- A 5-year view of Equity Ratio shows it stood at 0.59 in 2021, then dropped by 3.23% to 0.57 in 2022, then decreased by 2.36% to 0.56 in 2023, then dropped by 1.64% to 0.55 in 2024, then grew by 11.68% to 0.62 in 2025.
- Per Business Quant, the three most recent readings for NEO's Equity Ratio are 0.62 (Q4 2025), 0.61 (Q3 2025), and 0.61 (Q2 2025).